ASCO Annual Meeting | Conference

MK-1084 Yields Responses With Manageable Safety in KRAS G12C+ CRC

May 31st 2025

MK-1084 produced responses and was safe in KRAS G12C–mutated advanced colorectal cancer.

Dr Califano on MARIPOSA-2 Outcomes by Baseline Resistance Mechanisms in EGFR+ NSCLC

May 31st 2025

Raffaele Califano, MD, discusses molecularly stratified outcomes amivantamab with chemotherapy vs chemotherapy alone in patients with advanced EGFR-mutant NSCLC.

Dr Chahoud on Early Efficacy With Zanzalintinib Plus Nivolumab With/Without Relatlimab in ccRCC

May 31st 2025

Jad Chahoud, MD, MPH, MHA, shares early-phase data with zanzalintinib plus nivolumab with or without relatlimab-rmbw in previously untreated ccRCC.

Long-Term Data Underscore Role of Zanubrutinib in Treatment-Naive CLL/SLL With 17p Deletions

May 31st 2025

Zanubrutinib retained long-term efficacy as a frontline treatment in CLL/SLL harboring 17p deletions.

Sotorasib/Panitumumab Resistance May Be Linked to Genomic Alterations in KRAS G12C+ mCRC

May 31st 2025

Treatment resistance to sotorasib plus panitumumab may stem from genomic alterations in KRAS G12C–mutated CRC.

Nivolumab Plus Ipilimumab Shows Sustained PFS Benefit in MSI-H/dMMR mCRC

May 31st 2025

Nivolumab plus ipilimumab displayed superior PFS and PFS2 data vs chemotherapy and nivolumab monotherapy in mismatch repair-deficient colorectal cancer.

Frontline Anlotinib Plus CapeOX Elicits Similar Efficacy to SOC Therapy in RAS/BRAF Wild-Type mCRC

May 31st 2025

Anlotinib/chemotherapy demonstrated similar responses and PFS outcomes vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type mCRC.

ctDNA-Guided Chemo Does Not Yield RFS Benefit in Stage III Colon Cancer

May 31st 2025

Adjuvant chemotherapy decisions based on ctDNA status did not improve recurrence-free survival in stage III colon cancer.

T-DXd Represents a New SOC in Second-Line HER2+ Gastric/GEJ Cancer

May 31st 2025

T-DXd demonstrated clinically meaningful antitumor responses as second-line treatment in HER2-positive gastric/GEJ cancer.

Vepdegestrant Improves PFS in ESR1-Mutant ER+/HER2– Advanced Breast Cancer

May 31st 2025

PFS was improved when patients with ESR1-mutant ER-positive, HER2-negative advanced breast cancer received treatment with vepdegestrant vs fulvestrant.

ASCENT-04 Data Support Sacituzumab Govitecan Plus Pembrolizumab as New SOC in PD-L1+ TNBC

May 31st 2025

Frontline sacituzumab govitecan plus pembrolizumab improved PFS vs chemotherapy plus pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.

Adjuvant Chemotherapy Improves DFS in Molecularly Higher-Risk NSCLC

May 31st 2025

Adjuvant chemotherapy generated a DFS benefit over observation in patients identified as having higher-risk nonsquamous NSCLC per a prognostic assay.

KITE-363 Elicits Responses With Acceptable Tolerability in R/R B-Cell Lymphoma

May 30th 2025

Phase 1 data indicate that KITE-363 represents a promising therapeutic approach for patients with relapsed/refractory B-cell lymphoma.

Dr Strickler on the Efficacy of Sotorasib Plus Panitumumab/Chemo in KRAS G12C+ mCRC

May 30th 2025

John H. Strickler, MD, discusses the preliminary efficacy of sotorasib in combination with multiple agents across tumor types harboring KRAS G12C mutations.

ctDNA-Based MRD Provides Prognostic Value for First-Line Treatment in DLBCL

May 30th 2025

PhasED-Seq–assessed ctDNA-based MRD negativity was strongly associated with improved PFS after frontline treatment in patients with DLBCL.

Encorafenib/Cetuximab Plus Chemo Boosts PFS in BRAF V600E+ mCRC

May 30th 2025

Encorafenib plus cetuximab and mFOLFOX6 improved progression-free survival in BRAF V600E–mutated metastatic colorectal cancer.

Early Insights from ASCO 2025: Press Briefing Highlights with Clinical Impact

May 26th 2025

A 2025 ASCO press briefing previewed key advances in breast and lung cancer, HER2 diagnostics, and GLP-1s’ link to reduced cancer risk.

OncLive Polls Reveal Picks for Top Gastrointestinal Cancer Abstracts at ASCO 2025

May 23rd 2025

GI cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Inavolisib Plus Palbociclib and Fulvestrant Improves OS in PIK3CA-Mutant, HR+/HER2– Breast Cancer

May 22nd 2025

Inavolisib plus palbociclib and fulvestrant improved OS in PIK3CA-mutant, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer.

First-Line Maintenance Lurbinectedin Plus Atezolizumab Boosts Survival in ES-SCLC

May 22nd 2025

IMforte data highlight potential for lurbinectedin plus atezolizumab to become a new SOC for first-line maintenance treatment in ES-SCLC.